Data in support of fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice  by Luo, Du-Qiang et al.
Contents lists available at ScienceDirect
Data in Brief






E-mjournal homepage: www.elsevier.com/locate/dibData ArticleData in support of fumosorinone, a novel PTP1B
inhibitor, activates insulin signaling in
insulin-resistance HepG2 cells and shows
anti-diabetic effect in diabetic KKAy mice
Du-Qiang Luo a,n, Zhi-Qin Liu a,b, Ting Liu a, Chuan Chen a,
Ming-Yan Li b, Zi-Yu Wang b, Ruo-song Chen b, Gui-xiang Wei b,
Xiao-yi Wang b
a College of Life Sciences, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of
Education, Hebei University, Baoding 071002, PR China
b College of Pharmaceutical Sciences, key laboratory of pharmaceutical quality control of Hebei province,
Hebei University, Baoding 071002, PR Chinaa r t i c l e i n f o
Article history:
Received 16 March 2015
Accepted 19 March 2015
Available online 1 April 2015x.doi.org/10.1016/j.dib.2015.03.006
09/& 2015 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
espondence to: College of Life Sciences, Ke
n, Hebei University, No.180 Wusi East Roa
ail address: duqiangluo999@126.com (D.-Qa b s t r a c t
This data article contains data related to the research article entitled
“Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in
insulin-resistance HepG2 cells and shows anti-diabetic effect in
diabetic KKAy mice” in the Toxicology and Applied Pharmacology
[1]. Fumosorinone (FU) is a new inhibitor of protein phosphatase 1B
inhibitor, which was isolated from insect pathogenic fungi Isaria
fumosorosea. FU was found to inhibit PTP1B activity in our previous
study [2]. PTP1B is the physiological antagonist of the insulin signalling
pathway. Inhibition of PTP 1B may increase insulin sensitivity [3].
PTP1B has been considered promising as an insulin-sensitive drug
target for the prevention and the treatment of insulin-based diseases
[4]. We determined the effect of FU on the glucose consumption of IR
HepG2 cells. FU caused signiﬁcant enhancement in glucose consump-
tion by insulin-resistant HepG2 cells compared with control cells.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
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How data was acquired The cell plates were read on a Synergy HT microplate reader (PerkinElmer, MA, USA) at 550 nm.
Data format Analyzed
Experimental factors The IR HepG2 cells were exposed to FU (0-20μM) or Rosiglitazone (10μM RGZ) for 24 h.
Experimental features Glucose consumption in IR HepG2 was assessed.
Data source location Baoding, China
Data accessibility Data is provided in the article.2. Value of the data The glucose consumption was signiﬁcantly increased by 1.25- 20μM FU treatment.
 The data demonstrated the FU can improve insulin resistance in vitro.
 The data provided tested doses for further study in the research article.3. Experimental design, materials and methods
3.1. Cell culture
Hepatocellular carcinoma cells (HepG2 cells) possess the same bioactivity as normal hepatic cells,
which are valuable for investigating liver-associated functions and stable during many passages [5].
HepG2 cells were purchased from National Platform of Experimental Cell Resources for Sci-Tech
(Beijing, China). HepG2 cells were routinely grown in Minimum Essential Medium (MEM)
supplemented with 10% (v/v) fetal bovine serum, streptomycin (100μg/mL), and penicillin (100U/
mL), in a humidiﬁed atmosphere of 95 % air–5% CO2 at 37 1C.
3.2. Glucose consumption assay
The establishment of an insulin-resistant HepG2 cell model and glucose consumption were
performed according to the reported method [6,7] with a slight modiﬁcation. Brieﬂy, HepG2 cells
were cultured in 96-well cluster plates. After reaching conﬂuence, the cells were treated with 10−6
mol/L insulin for 24 h to induce insulin resistance, then add in different concentrations FU (0-20μM)
or Rosiglitazone (RGZ, 10μM, was purchased from TCI, Tokyo, Japan) [8] and incubated for 24 h, and
then incubated with 100nM insulin (was purchased from Sigma-Aldrich, USA) for 30 min. After this
incubation, glucose content in the culture medium was measured by glucose oxidase method (The
Glucose Analysis Kit was purchased from Applygen Technologies Inc. Beijing, China). The amount of
glucose consumed was calculated by measuring glucose concentrations of blank wells and subtracting
the remaining glucose in cell-plated wells [6]. As shown in Fig. 1. The glucose consumption was
signiﬁcantly increased by 1.25, 2.5, 5, 10 and 20μM FU treatment for 24 h. The effect of FU at a
concentration of 10 and 20μM on glucose consumption was similar to that of RGZ.4. Statistical analysis
The data were expressed as mean 7SD. Differences between the groups were compared by one-
way analysis of variance (ANOVA), followed by a Dunnett's multiple comparison test. Po0.05 was
considered to be statistically signiﬁcant differences between groups.
Fig. 1. Effect of FU on glucose consumption in insulin-resistant HepG2 cells. The insulin-resistant HepG2 cells were treated
with different concentration FU or RGZ for 24h, and then incubated with 100nM insulin for 30min. After this incubation,
glucose content in the culture medium was measured by glucose oxidase method. Values are the mean ± SD of three
independent experiments. nPo0.05, nnPo0.01 compared with control.
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